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AbstrAct
Studies indicate research ethics committee (REC) 
approval and clinician gatekeeping are two key 
barriers in recruiting children and young people 
(CYP) with life-limiting conditions (LLCs) and 
life-threatening illnesses (LTIs) and their families 
to research.
Objectives To explore the reported experiences, 
difficulties and proposed solutions of chief 
investigators (CIs) recruiting CYP with LLCs/LTIs 
and families in the UK.
Methods 61 CIs conducting studies with CYP 
with LLCs/LTIs and their families, identified from 
the UK National Institute of Health Research 
portfolio, completed an anonymous, web-
based questionnaire, including both closed and 
open-ended questions. Descriptive statistics and 
inductive and deductive coding were used to 
analyse responses.
results UK CIs cited limitations on funding, 
governance procedures including Research 
and Development, Site-Specific and REC 
approval processes, and clinician gatekeeping 
as challenges to research. CIs offered some 
solutions to overcome identified barriers such as 
working with CYP and their families to ensure 
their needs are adequately considered in study 
design and communicated to ethics committees; 
and designing studies with broad inclusion 
criteria and developing effective relationships 
with clinicians in order to overcome clinician 
gatekeeping.
conclusions Many of the challenges and 
solutions reported by UK CIs have applicability 
beyond the UK setting. The involvement 
of clinicians, patients and their families at 
the inception of and throughout paediatric 
palliative care research studies is essential. Other 
important strategies include having clinician 
research champions and increasing the visibility 
of research. Further research on the perspectives 
of all stakeholders, leading to mutually agreed 
guidance, is required if care and treatment are to 
improve.
IntrOductIOn
In the UK, around 32 per 10 000 children 
have a life-limiting condition (LLC) or 
life-threatening illness (LTI).1 LLCs are 
those from which there is no reasonable 
hope of cure and from which children 
and young people (CYP) will die. LTIs are 
those for which curative treatment may be 
possible but can fail.1 CYP with LLCs/LTIs 
are likely to receive a palliative approach 
to care, often alongside disease-directed 
treatments.2 In this population, the phys-
ical, social and psychological needs of 
patients and families are often great and 
may not be well addressed.3 4 There is a 
lack of evidence in paediatric palliative 
care (PPC) and further research of all 
types is required.5–7 
A systematic review exploring recruit-
ment strategies in studies conducted 
in this field found that invitation and 
recruitment of participants were under-re-
ported.8 Recruitment is challenging at all 
stages including identification of poten-
tial participants, approach and invitation 
to participate, and the initial consent 
process.8–12
An ever-increasing emphasis on the 
importance of involving children and 
their families from the study design stage 
forward has occurred at a time when there 
have also been changes in the UK gover-
nance and regulation of research.13 As 
of 1 January 2015, the Health Research 
Authority (HRA) was established to 
streamline the process of obtaining ethical 
and regulatory approvals and Research 
and Development (R&D) approval has 
changed.14
Despite researchers being responsible 
for navigating these complex approval 
processes and many chief investigators 
(CIs) having several years’ experience 
in the field of palliative care, very little 
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research has directly explored their views about 
barriers encountered and suggested solutions to over-
come these. Chen and colleagues15 conducted an 
interview study of leading researchers in palliative care 
in the USA in order to explore barriers to research 
they had encountered. However, this work was not 
focused exclusively on studies conducted with chil-
dren. Therefore, we conducted a scoping survey of 
PPC researchers at the 7th International PPC confer-
ence in 2015. This initial survey reported clinician 
gatekeeping and research ethics committees (RECs) 
as significant barriers to recruitment in this popula-
tion and the full results are reported elsewhere.16 We 
used these data to inform the structure and content of 
a larger and more detailed online national survey to 
further our understanding.
In this paper, we report on the UK wide online 
survey which collected data from CIs recruiting CYP 
with LLCs/LTIs and their families, with attention not 
only to reported barriers to research but also sugges-
tions for solutions.
MethOds
development of the survey
An online survey was built using OPINIO survey 
software.17 As well as building on what we had 
learnt from the scoping survey of PPC researchers,16 
the UK wide survey was also informed by a scoping 
review of barriers to research in palliative care with 
paediatric and with adult populations.9–12 15 18–25 
That review identified six relevant domains: (1) 
ethical issues; (2) institutional capacity; (3) funding 
issues; (4) physician-related factors; (5) population 
factors and (6) recruitment and consent processes. 
The UK wide survey was drafted by the research 
team which included senior researchers experienced 
in conducting palliative care research in a number of 
populations including CYP and their families, as well 
as more junior researchers who are often responsible 
for navigating governance procedures and recruiting 
research participants.
The draft survey was piloted by the research team 
among both junior and senior academic colleagues, 
including three statisticians, and was modified in 
an iterative process based on their feedback. Items 
were presented in a variety of formats including 
multiple response, Likert scale and open-ended 
questions.
The final version of the survey included 28 ques-
tions and was divided into three sections collecting 
data on: (1) CI’s most recent project involving CYP 
with LLCs/LTIs/their families—including sections 
on ethical and regulatory approvals and researcher 
access to patients and families via clinicians; (2) 
CI’s experiences of research with this population in 
general; (3) demographic information on respon-
dents. A copy of the survey is included in the online 
supplementary appendix A.
Participants and setting
The UK National Institute of Health Research (NIHR) 
Clinical Research Network (CRN) portfolio was 
searched to identify all CIs conducting studies with 
CYP (aged 0–18 years) with LLCs/LTIs and their fami-
lies which were either open or closed (ie, collecting 
data) between March 2011 and 2016. There were no 
restrictions on methodology of included studies. Deci-
sions on whether an illness or condition was consid-
ered to be LL or LT were guided by Hain’s directory of 
LLCs26 which includes International Classification of 
Diseases-10 codes. If there was uncertainty about eligi-
bility, CIs were included initially as the survey began by 
asking whether respondents had been involved with a 
study that recruited CYP with LLCs/LTIs or their fami-
lies over the past 5 years and automatically terminated 
if they selected ‘No’.
All potentially eligible and eligible CIs (n=257) 
were sent a personalised invitation via e-mail in April 
2016 and a reminder was sent 1 month later. The first 
page of the survey served as an information sheet for 
respondents, including the project aims, definitions 
for LLCs/LTIs and approximate time for comple-
tion (15 min). Consent to participate was considered 
implied by voluntary completion of the survey.27
study design
We used a mixed methods design; qualitative open-
ended items were present to validate and expand on 
the quantitative components.28 Closed-ended ques-
tions were analysed using descriptive statistics. We 
analysed responses to open-ended questions using 
the broad principles of grounded theory, with a focus 
on inductive coding while acknowledging the use of 
deductive coding, as appropriate.29
ethics
Ethical approval was granted from the UCL Research 
Ethics Committee (UCL ethics Project ID: 8513/001) 
on 11 March 2016.
results
sample
Of the 257 CIs invited to take part, 71 answered 
the first eligibility question on the survey; of these 4 
answered ‘No’ to this and 6 answered ‘Yes’ but then 
answered no further questions. Twenty-four per cent 
(61/257) of those who were invited to take part, did 
so beyond the initial eligibility question. Respondent 
characteristics are shown in table 1.
characteristics of research project for which cI most 
recently completed data collection
Studies were diverse in nature and key features of these 
projects are summarised in table 2. CYP in the studies 
had a range of LLCs/LTIs, including for example cystic 
fibrosis, cerebral palsy, cancer and Duchenne muscular 
dystrophy.
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barriers to research with cYP with llc/ltI and their families
Ethical and regulatory approvals
For the most recent project for which CIs had 
completed data collection, 44% stated that they expe-
rienced difficulties gaining R&D approval and 26% 
site-specific approval (SSA). Only 14% said they had 
difficulties obtaining REC approval (table 3). Respon-
dents emphasised that it was both the complexity and 
duration of the R&D/SSA approval processes that 
made these processes challenging.
Notably, 63% of CIs reported having to make 
changes after REC review when compared with 27% 
of CIs after R&D review (table 3). Forty-five per cent 
(18/40) of CIs found the changes to study conduct and 
materials required by regulators to be useful. For 45% 
(25/56) of respondents, it took >6 months to obtain 
all necessary approvals.
Researcher access to patients and families via clinicians
For the most recent project for which CIs had 
completed data collection, 32% (17/53) of respondents 
rated the working relationship between clinicians and 
researchers as extremely effective and 51% (27/53) as 
effective. However, such a positive assessment was not 
mirrored in free text responses, where CIs emphasised 
how the quality of working relationships could vary by 
individual, team and centre. Variability in clinicians’ 
willingness to recruit participants was particularly 
highlighted, as illustrated by the comment below:
Some clinicians act as gatekeepers and do not give 
families the opportunity to decline or accept a study 
(CI 10, researcher).
Funding
Regarding their experiences in research with CYP with 
LLCs/LTIs and their families in general, the majority of 
CIs (51%; 27/53) reported that funding was the biggest 
research barrier encountered. This was especially true 
for those in a clinical (73%; 8/11) rather than a clinical 
and research (44%; 12/27) or solely research (47%; 
7/15) position (figure 1).
respondents’ proposed solutions to identified barriers 
and challenges to research with cYP with llc/ltI and their 
families
Respondents proposed recommendations that are 
likely to be applicable, regardless of the population 
under study. These included having a well thought 
out question and methodology to improve chances of 
obtaining funding, attending ethics meetings in person 
and getting advice from R&D, RECs and others who 
have been through the approval process. There were 
also a number of recommendations that related specif-
ically to PPC research. These are detailed below:
Table 1 Characteristics of CIs
Variable n (%)
Type of post (n=53)
  Combined (research and clinical) 27 (51)
  Research 15 (28)
  Clinical 11 (21)
Discipline (n=53)
  Medicine 33 (62)
  Nursing 5 (9)
  Social science 4 (8)
  Allied Healthcare 3 (6)
  Education 1 (2)
  Natural science 1 (2)
  Other 6 (11)
Time spent researching with CYP with LLC/LTI and their 
families (n=53)
  >16 years 21 (40)
  11–15 years 7 (13)
  6–10 years 12 (23)
  1–5 years 12 (23)
  <1 year 1 (2)
Number of studies recruiting CYP with LLC/LTI CI has been 
involved in (n=52)
  11+ 10 (19)
  6–10 16 (31)
  2–5 11 (21)
  1 15 (29)
CI, chief investigator; CYP, children and young people; LLC, life-limiting 
condition; LTI, life-threatening illness.
Table 2 Characteristics of research project for which CIs most 
recently completed data collection
Variable N (%)
Type of project (n=61)
  Multicentre 46 (75)
  Single site 15 (25)
Methodology (n=61)
  Randomised controlled trial 18 (30)
  Observational study 14 (23)
  Non-randomised trial 8 (13)
  Interviews 7 (11)
  Mixed methods study 7 (11)
  Questionnaire 4 (7)
  Focus group 2 (3)
  Participant observation 1 (2)
Use of audio/video/the internet (n=60)
  Audio recording 21 (35)
  Video 7 (12)
  Internet 7 (12)
Study participants (n=60)
  Children and young people 57 (95)
  Parents 27 (45)
  Health professionals 19 (32)
  Siblings 8 (13)
Language of children and young people and families 
(n=61)
  English as a second language 44 (72)
CI, chief investigator.
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Involving CYP and their families throughout the research process
The importance of involving CYP and families early in 
the research process was strongly indicated. Ensuring 
that ‘the study design adequately takes into consider-
ation the participant families’ needs’ (CI15, research 
and clinician) was emphasised. Many CIs spoke about 
the importance of involving CYP in the design of 
clear and appropriate participant information sheets. 
Written information sheets might not be the most 
appropriate, as reflected by the comment from one CI 
below:
Our population had a lot of parents who either 
didn't read and write in English or who had limited 
literacy in any language. I understand this to be 
common to many palliative conditions. In practice 
the written information on consent sheets and 
information sheets were not helpful in the slightest 
(CI 17, researcher).
Respondents underscored how feedback from CYP and 
their families must be included in ethics applications:
Consult with members of the communities you plan 
to involve… Record their opinions and include 
them in your application for ethical approval (CI 
20, researcher).
Designing studies with broad inclusion criteria
Respondents indicated that given the usually small 
number of eligible CYP for PPC research, inclusion 
criteria should be broad to ensure a large enough 
sample size is reached:
Design studies that will not exclude too many 
patients. This is very important in children (CI 33, 
clinician).
Involving clinicians early on in the research process
It was argued that clinicians should be involved in the 
design, development and conduct of research from the 
outset:
Make sure you establish excellent relationships 
with clinicians and parent and patient groups well 
in advance of beginning your research (CI 27, 
researcher and clinician).
Embedding researchers into clinical teams
Seventy-five per cent of CIs (40/53) reported that 
embedding researchers into clinical teams would have 
a major impact on improving researcher access to 
patients and families. However, the challenges in this 
approach were also noted. As one CI stated:
The medical staff in my 'team' have NO interest 
in anything other than Clinical Trials of an 
Investigational Medicinal Product (CTIMPs) (CI 26, 
researcher and clinician).
One CI suggested that to overcome clinician gate-
keeping researchers should be permitted to recruit for 
themselves:
Interestingly, parents always wanted to participate…I 
would suggest all researchers should recruit for 
themselves and not allow clinicians to facilitate it at 
all as it can cause unnecessary gate-keeping (CI 17, 
researcher).
However, as highlighted by one CI, this is problematic 
where recruiting via clinicians is ‘an ethical require-
ment of the study’ (CI 19, researcher and clinician).
dIscussIOn
We undertook this work to increase our understanding 
of current barriers to conducting research with CYP 
with LLCs/LTIs and their families, and to consider how 
these might be overcome. Our data reflect the views 
of CIs conducting studies in the UK with funds from 
NIHR or organisations that meet quality criteria for 
inclusion in the NIHR Portfolio (eg, Wellcome Trust, 
Table 3 Difficulty and changes required for gaining approvals 
for most recent research project
Variable N (%)
Whether difficulties were experienced gaining approval 
(n=56)
  R&D (n=55) 24 (44)
  SSA (n=46) 12 (26)
  Coordination of approval systems (n=56) 12 (21)
  REC (n=56) 8 (14)
  CAG (n=5) 1 (20)
  Review within institution (n=40) 1 (3)
  Other (n=12) 1 (8)
Most difficult approval process (for those experiencing 
difficulties) (n=32)
  R&D 15 (47)
  SSA 7 (22)
  Coordination of approval systems 4 (13)
  REC 1 (3)
  CAG 1 (3)
  Review within institution 0 (0)
  Other 4 (13)
Whether changes were required as a result of review process 
(n=56)
  R&D (n=55) 15 (27)
  SSA (n=46) 5 (11)
  REC (n=56) 35 (63)
  CAG (n=5) 2 (40)
  Review within institution (n=40) 7 (18)
  Other (n=12) 3 (25)
Area where the biggest change was requested (n=40)
  Information sheet 19 (48)
  Consent/assent 9 (23)
  Data collection methods 4 (10)
  Sample size 2 (5)
  Data storage 1 (3)
  Other 5 (13)
R&D, Research and Development; SSA, Site Specific Approval; REC, 
Research Ethics Committee; CAG, Confidentiality Advisory Group.
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Cancer Research UK, The Health Foundation). As 
emphasised by the results, particular challenges arise 
in PPC research: opportunities for funding are scarcer 
both through mainstream agencies and specific calls, 
RECs may be apprehensive about approving work in 
this area and overloaded clinicians may also have anxi-
eties about the appropriateness of some research work. 
CIs emphasised the importance of involving clini-
cians, CYP and families at the inception of studies and 
embedding researchers into clinical teams, in order to 
overcome some of the identified difficulties.
What is already known about this topic and what this 
research/review adds
The findings of this study in the UK are consistent with 
others exploring similar issues such as that by Chen et 
al reporting on results of a survey of US National Insti-
tute of Health funded CIs.15 This underscores how 
regardless of differences between countries and health-
care systems, problems encountered in this area are 
common. Unique to our study was the challenge that 
CIs raised with regard to the R&D approval process. 
It is unclear, however, whether these perceived diffi-
culties are specific to PPC research and the extent to 
which such obstacles will have persisted since the estab-
lishment of the HRA and streamlining of processes in 
the UK in 2015. This is something that would be an 
important area for further study.
Also, unique to our study was the fact that CIs were 
explicitly asked to propose solutions to overcome 
barriers. The stated importance of co-designing research 
projects from the outset with CYP and their families is in 
line with policy and is of particular importance for PPC 
research to address the concerns of RECs and clinicians 
who can have distorted assumptions about families’ 
views about potential participation.8 12 30 31 Furthermore, 
it was underlined by CIs how the biggest changes were 
required to information sheets and then the consent/
assent process before approvals were granted and, conse-
quently, the importance of involving CYP in the design 
of information sheets was specifically mentioned. It was 
argued that written information sheets might not be the 
most appropriate for the PPC population. Although 
focused on decision making for participation in health-
care trials involving CYP (the benefits and burden of 
participation are likely to differ for non-trial studies), 
a current trial is underway to evaluate how multimedia 
interventions, including textual, audio and visual infor-
mation compare with written information.32
The involvement of clinicians from the study design 
stage was viewed as important by CIs and should be 
considered a priority in future guidance. Taking a 
participatory approach to research, with health profes-
sionals involved early on, has been shown to be effec-
tive in prior palliative care research,33 both in terms 
of the representativeness of the sample and positive 
perspective of health professionals when collecting the 
data.33
The perceived importance of embedding researchers 
into clinical teams to improve access to patients 
and families is in line with the experiences of Blue-
bond-Langner and colleagues, who embedded 
researchers in a longitudinal study and enabled 
different perspectives of multiple participants to be 
captured in real time.34
Figure 1 CIs views of the biggest barriers to research with CYP with LLCs/LTIs and their families. CI, chief investigator; CYP, children 
and young people; LLC, life-limiting condition; LTI, life-threatening illness. 
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However, as emphasised by CIs in our survey, even if 
clinicians are involved early on in the research process 
and researchers are embedded into clinical teams, 
recruitment via clinicians can still be a challenge.35 A 
review of interventions conducted to improve recruit-
ment to randomised controlled trials found that the 
impact of interventions aimed at recruiters, specifically 
providing additional education, was unclear.36 We 
suggest the development of clinician research cham-
pions to facilitate research within their teams. When 
reporting work carried out with the active co-opera-
tion of clinicians, these individuals should be invited 
to contribute as full authors for peer-reveiwed manu-
scripts or at least be acknowledged within these. Use of 
research registers, publicising research on social media 
or university websites, and liaising with special interest 
groups for rarer LLCs and LTIs are possible mecha-
nisms to increase the profile and visibility of research 
within society, so interested families can request to 
participate in studies. A further important strategy, 
adopted as part of a participatory approach to research 
in this study and in other research areas,37 is ensuring 
that there is a lay representative on the research team.
strengths and limitations of the study
The use of the NIHR portfolio to identify CIs meant 
that the scope of the survey could be nationwide. 
However, a ‘true’ population denominator could not 
be calculated as it was sometimes difficult to assess 
whether some CIs should have been included, for 
example, where there was limited information about 
the condition studied.
By only using the NIHR portfolio, the perspectives 
of those who conducted studies without NIHR or 
NIHR recognised funding sources (eg, studies funded 
by some approved charities)38 were not included. The 
use of the portfolio to identify participants also meant 
that clinicians were likely to be over-represented in the 
sample. However, the number of highly experienced 
researchers in the study (n=61) provided a rich source 
of data for analysis.
Conducting a survey that included both closed and 
open-ended questions provided depth and clarity in 
responses. This was particularly striking where CIs 
described clinician involvement with introducing the 
study to patients/families as positive in a closed ques-
tion but in open-ended responses, variability in clini-
cians’ willingness to recruit participants to studies was 
highlighted.
directions for further research
Our survey was conducted from the perspectives of 
CIs. There remains little in the literature on what 
other clinicians, parents and CYP perceive as barriers 
to PPC research and how these might be overcome. 
Seeking the perspectives of funding bodies would also 
be useful. However, identifying suitable interventions 
in this area is likely to be complex. Informed by the 
findings of this research, our group, in collaboration 
with the HRA, is now conducting a more in-depth 
study of the constraints and concerns of RECs with the 
goal of reducing barriers inherent in current research 
governance processes.39
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